Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Amines Stories

2013-07-30 12:28:17

Once-Daily Dopamine Agonists Will Progressively Dominate This Market-Leading Drug Class, According to a New Report from Decision Resources BURLINGTON, Mass., July 30, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of key current brands and the launch of three new therapies will help sustain the Parkinson's disease (PD) market throughout the 2012-2022 forecast period,...

2013-07-30 10:49:05

American Heart Association/European Society of Cardiology Scientific Statement Healthcare professionals are urged to counsel heart and stroke patients on how to resume a healthy sex life, according to a joint statement published in the American Heart Association journal Circulation and the European Heart Journal. It is the first scientific statement to offer detailed guidance for patients. "Patients are anxious and often afraid sex will trigger another cardiac event –...

2013-07-30 08:33:20

--Extends Patent Life to 2030 for Novel Agent that Demonstrated Rapid Onset, Robust Efficacy and Good Safety in a Phase II Trial-- EVANSTON, Ill., July 30, 2013 /PRNewswire/ -- Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced issuance of a new U.S. patent for its lead compound, GLYX-13. The new patent, which covers methods of treating major depressive disorder, expires in 2030. GLYX-13 has...

2013-07-26 11:16:52

Testing dropped once funding from pharmaceutical industry was discontinued Significant advances have taken place in the management of patients with advanced and metastatic non–small-cell lung cancer (NSCLC) over the last 5 years. Traditionally, all advanced NSCLC patients were treated in a similar manner. More recently, the importance of pathologic subtype has been recognized. Data from several randomized trials demonstrate that epidermal growth factor (EGFR) mutation...

2013-07-25 16:25:38

SAN DIEGO, July 25, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that BELVIQ(®) (lorcaserin HCl) has been nominated for the 2013 Prix Galien USA Award in the Best Pharmaceutical Agent category. BELVIQ is approved by the US Food and Drug Administration (FDA) for chronic weight management in adults. The Prix Galien Award is considered one of the biomedical industry's top accolades, as it recognizes outstanding achievements in improving the human...

2013-07-24 20:21:06

WASHINGTON, July 24, 2013 /PRNewswire-USNewswire/ -- After its Board of Directors meeting in Washington, D.C., the Electric Drive Transportation Association (EDTA) today announced its new leaders and additions to its Board. Tanvir Arfi, president of Bosch Automotive Service Solutions, begins his tenure as the association's new chair. "Serving as chairman of EDTA provides me with a unique opportunity to support electric drive transportation by combining my personal passion with...

2013-06-30 23:00:54

Achieve Clinical is Conducting a Double-Blinded, Randomized, Placebo-Controlled, Proof of Concept Phase 2a Study Exploring the Safety and Efficacy of a New Drug for the Treatment of Patients with Fibromyalgia Birmingham, Alabama (PRWEB) June 30, 2013 ESTIMATED STUDY DURATION: 16-19 weeks. This includes 5 – 28 days in screening followed by 16 weeks of blinded study drug treatment. BACKGROUND & RATIONALE: Chronic pain affects an estimated 116 million American adults-- more than the...

2013-06-30 23:00:50

Avail Clinical is conducting an 11-week, Phase 2 Multicenter, Randomized, Double−Blind, Parallel−Group, Placebo−Controlled Study of a new drug in Subjects with Fibromyalgia (FM). DeLand, Florida (PRWEB) June 30, 2013 *To see if you qualify for this Fibromyalgia Clinical Trial in Florida, visit Avail Clinical Research on the web (http://www.availclinical.com) or contact us directly at (386) 785-2404. STUDY POPULATION: Adults with fibromyalgia DURATION OF STUDY PARTICIPATION: Up to...

2013-06-27 23:20:05

BioPlus selected as a specialty pharmacy for the new Tarceva network; now authorized to dispense this oncology medication. Altamonte Springs, FL (PRWEB) June 27, 2013 The medication Tarceva® (erlotinib) from Genentech and Astellas Pharma US, Inc. will no longer be distributed through retail pharmacies, effective July 1, 2013. Tarceva will be supplied through BioPlus Specialty Pharmacy (BioPlus) and other select specialty pharmacies. Tarceva is a once daily oral non-chemotherapy...

2013-06-20 08:27:00

MONMOUTH JUNCTION, N.J., June 20, 2013 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today announced that it has named Janet Penner as President of its new generic pharmaceuticals business. Tris' generic pharmaceuticals business, with its own distinct sales, marketing and distribution, will be responsible for commercializing Tris' Abbreviated New Drug Applications (ANDAs) while leveraging Tris' considerable...